Biocept Inc (BIOC.OQ) Quote| Reuters.com
Edition:
United States

Biocept Inc (BIOC.OQ)

BIOC.OQ on NASDAQ Stock Exchange Capital Market

0.67USD
12:42pm EDT
Change (% chg)

$0.00 (+0.68%)
Prev Close
$0.67
Open
$0.66
Day's High
$0.67
Day's Low
$0.66
Volume
3,128
Avg. Vol
43,075
52-wk High
$3.09
52-wk Low
$0.57

BIOC.OQ

Chart for BIOC.OQ

About

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally... (more)

Overall

Beta: --
Market Cap(Mil.): $16.61
Shares Outstanding(Mil.): 24.97
Dividend: --
Yield (%): --

Financials

  BIOC.OQ Industry Sector
P/E (TTM): -- 41.52 36.15
EPS (TTM): -0.96 -- --
ROI: -169.17 11.61 14.31
ROE: -275.31 13.65 15.51

BRIEF-Biocept launches proprietary liquid biopsy test to detect RET fusions in patients with lung cancer

* Biocept launches proprietary liquid biopsy test to detect RET fusions in patients with lung cancer Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

May 19 2016

BRIEF-Biocept Q1 loss per share $0.25

* Q1 revenue rose 47 percent to $221,000 Source text for Eikon: Further company coverage: (Bengaluru Newsroom +1-646-223-8780)

May 12 2016

BRIEF-Biocept announces pricing of $5 mln public offering

* Biocept, inc. Announces pricing of $5 million public offering of common stock and warrants

Apr 29 2016

BRIEF-Biocept Inc proposes public offering of common stock and warrants

* Biocept inc. Announces proposed public offering of common stock and warrants Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Apr 28 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.